Candel Therapeutics
Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.
Something off on this page? Send us feedback.
Profile
Develops off-the-shelf viral immunotherapies for solid tumors, led by aglatimagene in prostate cancer and lung cancer and linoserpaturev in recurrent high-grade glioma. Operates as a pre-revenue, one-segment biotech whose progress depends on clinical trials, FDA review, manufacturing readiness, and financing.
Develops off-the-shelf viral immunotherapies designed to trigger systemic anti-tumor immune responses in solid tumors. Aglatimagene besadenovec anchors the adenovirus platform, with BLA readiness in localized prostate cancer and a global pivotal AURORA trial in metastatic non-squamous NSCLC.
Linoserpaturev leads the HSV platform in recurrent high-grade glioma, while enLIGHTEN remains a preclinical HSV-based discovery platform for additional solid-tumor programs. The company reports one segment and has not generated product sales.
Execution is centered in Needham, Massachusetts, with development priorities tied to FDA review, clinical-trial readouts, launch-readiness work, manufacturing planning, and access to external capital.
Company facts
Key statistics
Year to date +140% · Average volume (30d) 1.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jul 29, 2026 | H.C. Wainwright | Reiterate | Buy | $23 | |
| Jul 13, 2026 | Stifel Nicolaus | Target | $22 | ||
| Oct 27, 2025 | Stephens | Target | $15 | ||
| Sep 3, 2025 | B of A Securities | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.24 | −$0.52 | −118.6% | — | — | — | +10.49% |
| May 14, 2026Q1 FY26 | −$0.22 | −$0.14 | +36.4% | — | — | — | −1.57% |
| Mar 12, 2026Q4 FY25 | −$0.24 | −$0.54 | −125.0% | — | — | — | −6.22% |
| Nov 13, 2025Q3 FY25 | −$0.17 | −$0.21 | −23.5% | — | — | — | +0.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$8.1M | −$11.2M | −$13.2M | −$15.8M | −$16.3M | −$26.7M | |
| Net income | $7.4M | −$4.8M | −$11.3M | −$29.5M | −$8.9M | −$38.9M | |
| Diluted EPS | $0.23 | −$0.09 | −$0.21 | −$0.54 | −$0.14 | −$0.52 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $124.0K · FY22 $124.0K · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $201.6M · Total debt $49.5M · Total assets $208.1M · Shareholders' equity $126.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 73.27M · Float 56.81M · 77.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 10.99M | 15.00% | 13F | May 15, 2026 |
| RTW Investments, LP | 6.42M | 8.80% | 13G | May 15, 2026 |
| Paul B Manning | 5.79M | 7.90% | 13D | Mar 18, 2026 |
| BlackRock, Inc. | 4.83M | 6.60% | 13G | Jul 27, 2026 |
| Acorn Capital Advisors, LLC | 3.50M | 4.77% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Seshu Tyagarajan | officer: Chief Technology Officer | −7,000 | $12.00 |
| Jun 29, 2026 | Seshu Tyagarajan | officer: Chief Technology Officer | −7,000 | $10.02 |
| Jun 29, 2026 | Francesca Barone | officer: Chief Scientific Officer | −23,447 | $10.06 |
| Feb 23, 2026 | Paul B. Manning | director | +550,458 | $5.45 |
Peers
- Replimune Group
Direct HSV oncolytic peer with BLA-stage RP1
- CG Oncology
Late-stage oncolytic immunotherapy peer in bladder cancer
- Genelux
Oncolytic vaccinia peer with lung and ovarian programs
- Oncolytics Biotech
Pelareorep viral immunotherapy peer in GI solid tumors
- Amgen
Approved oncolytic viral therapy benchmark
- Iovance Biotherapeutics
Nonviral solid-tumor immunotherapy peer with NSCLC overlap
- Calidi Biotherapeutics
Earlier-stage oncolytic-virus delivery peer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Candel Therapeutics | $13.07 | +0.08% | $957.6M | — | — | — | — |
| Replimune Group | $15.45 | −0.39% | $1.30B | — | — | — | — |
| CG Oncology | $73.91 | −0.57% | $6.56B | — | — | 1,052.8 | — |
| Genelux | $2.66 | −0.31% | $119.3M | — | — | 14,909.4 | −98.2% |
| Oncolytics Biotech | $0.8526 | −0.79% | $86.0M | — | — | — | — |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Iovance Biotherapeutics | $8.03 | +0.06% | $3.58B | — | — | 11.0 | +65.7% |
| Calidi Biotherapeutics | $1.32 | +0.76% | $607.8K | — | — | — | — |
| Median | 26.9 | 18.4 | 531.9 | +9.7% |